BridgeBio Oncology Therapeutics, Inc. (BBOT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.77 (-2.45%), Market cap $0.65B, 52-week low–high $7.66 ~ $13.73.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203,
Financial statements, price targets, institutional (13F) holdings and related news for BridgeBio Oncology Therapeutics, Inc. are updated in real time on BlackAll Trade.
BridgeBio Oncology Therapeutics, Inc. trades at $4.77 (-2.45%). Real-time quotes and charts are available on BlackAll Trade.
BridgeBio Oncology Therapeutics, Inc. has a market cap of about $0.65B.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinosit